THC and Liver Toxicity: Why Computer Predictions and Cell Results Are Not Patient Diagnoses
Computer-predicted pathways and altered gene expression in cultured cells can suggest a toxicity mechanism without establishing liver injury in a patient. A 2025 THC study illustrates the difference between mechanistic investigation and clinical causal diagnosis.
The evidence came from several research layers
Zou and colleagues combined network toxicology, pathway analysis, molecular docking, and experiments using L-02 cell cultures. They identified candidate targets and examined mRNA responses after THC treatment.
This was computational and in-vitro research. It was not a cohort of cannabis users with liver disease, a human dosing trial, or an animal study documenting organ injury. Culture-medium exposures also are not human whole-blood concentrations.
Predicted binding and measured expression differ
Molecular docking estimates how a molecule may interact with a protein structure under modeled conditions. It does not independently demonstrate binding in a living patient. The experimental work found changes in selected target-gene mRNAs, supporting further examination of the proposed pathways.
Changes in mRNA do not necessarily produce corresponding changes in protein abundance or function. They also do not specify the magnitude of clinical liver damage, its duration, or whether an observed laboratory abnormality in a patient has the proposed cause.
The authors’ limitations are consequential
The paper acknowledges the absence of protein-level experiments and in-vivo validation. It also does not establish how the degree of hepatotoxicity varies across different THC doses. Consequently, the study does not supply a human diagnostic concentration, a clinical incidence estimate, or a safe-versus-toxic exposure boundary.
The language of a pathway analysis should therefore remain hypothesis-focused. A network association does not become a proven disease mechanism simply because multiple databases point to the same target.
Applying it to an actual liver-injury allegation
A case-specific assessment requires a documented product and exposure timeline, clinical findings, serial liver testing, other medications and substances, and evaluation of alternative causes. The proposed mechanism must also fit the injury pattern and relevant exposure conditions.
This paper can help formulate mechanistic questions. It cannot establish that cannabis caused a particular person’s liver disease or exclude other causes without the clinical evidence necessary for that conclusion.
Related evidence
For the distinction between detecting cannabis and establishing its significance, see our analysis of exposure, impairment, and crash-risk evidence.
Primary research
Uncovering mechanism of hepatotoxicity diseases caused by tetrahydrocannabinol based on novel network toxicology and experimental verification. Scientific Reports, 2025. DOI: 10.1038/s41598-025-97523-0.
